News stories about TrovaGene (NASDAQ:TROV) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. TrovaGene earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 48 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- TrovaGene (NASDAQ:TROV) vs. Biocept (BIOC) Head-To-Head Survey (americanbankingnews.com)
- Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075 – PR Newswire (press release) (prnewswire.com)
- TrovaGene, Inc. (NASDAQ:TROV) PT Set at $4.00 by Maxim Group (americanbankingnews.com)
- PRA to conduct Ph Ib/II clinical trial of PLK1 inhibitor (outsourcing-pharma.com)
Shares of TrovaGene (NASDAQ:TROV) traded up 0.81% on Monday, reaching $1.25. 317,690 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $0.88 and a 200-day moving average price of $1.47. TrovaGene has a 12-month low of $0.61 and a 12-month high of $5.98. The company’s market cap is $38.72 million.
TROV has been the topic of several research reports. Maxim Group set a $4.00 price objective on shares of TrovaGene and gave the stock a “buy” rating in a research note on Thursday. Cantor Fitzgerald set a $8.00 price objective on shares of TrovaGene and gave the stock a “buy” rating in a research note on Saturday, March 18th. Zacks Investment Research lowered shares of TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, March 15th. Finally, Piper Jaffray Companies lowered shares of TrovaGene from a “neutral” rating to an “underweight” rating in a research note on Thursday, March 16th.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286133/trovagene-nasdaqtrov-receives-daily-coverage-optimism-rating-of-0-19.html
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.